Acutaas Chemicals Q3 FY26 Earnings Call Transcript Released
Acutaas Chemicals released its Q3 FY26 earnings call transcript. The company reported strong revenue growth and record margins, with PAT crossing ₹100 crore. Revenue guidance for FY26 was revised up to 30% growth, and EBITDA margin guidance was increased to 32-35%. New initiatives in battery and semiconductor chemicals are progressing.
The transcript details significant financial performance, strategic business expansion into new sectors like battery and semiconductor chemicals, and upward revisions in financial guidance, all of which are material to investors.
The company reported strong financial results, revised revenue guidance upwards, and provided positive updates on new business verticals and strategic initiatives.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has released the transcript of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call, held on January 28, 2026, featured management including Chairman and Managing Director Mr. Naresh Patel, Vice President of Strategy Mr. Abhishek Patel, and Chief Financial Officer Mr. Bhavin Shah.
During the call, the management discussed the company's strategic initiatives, including growth in pharmaceutical intermediates, the new battery chemicals business with a recently inaugurated facility at Jhagadia, and early-stage semiconductor chemicals business through joint ventures in South Korea. They highlighted that by FY2028, these three verticals are expected to operate as independent, self-sustaining growth engines.
Financial performance for Q3 FY26 showed revenue from operations close to ₹400 crores with record margins, leading to a profit after tax exceeding ₹100 crores. The company revised its revenue guidance upwards to approximately 30% growth for FY26 and upgraded its EBITDA margin guidance for the full year to 32%-35% from 28%-30%. For the nine months of FY26, revenue was ₹906.6 crores, with EBITDA doubling and PAT more than doubling compared to the previous year.
Discussions also covered the performance of the Advanced Pharmaceutical Intermediates segment (revenue of ₹351.1 crores in Q3 FY26, up 47.0% YoY) and the Specialty Chemicals segment (revenue of ₹42.1 crores, up 16.5% YoY). Capital expenditure for the nine-month period was ₹143 crores, mainly for the battery chemical project and a pilot plant. The company also noted that its CMD, Mr. Naresh Patel, was recognized among Hurun India's Top 200 Self-made Entrepreneurs.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.